Vir Shares Rally 25% on Cancer Licensing Deal With Sanofi, Trial Updates

Dow Jones

2024-11-02

By Jasmine Li

Shares of Vir Biotechnology surged after the company provided updates on its pipeline of potential treatments for hepatitis and cancer.

The stock rose 25% to $9.34 in midday trading on Friday. Shares are down 8.5% this year.

After the market closed on Thursday Vir reported lower revenue and a wider loss in the third quarter, citing higher research and development expenses from the closing its licensing deal with Sanofi.

The deal gives Vir the exclusive worldwide license to three T-cell engager programs with potential applications in a range of cancers, the company said. Vir also gained exclusive use of a proprietary masking platform for oncology and infectious disease.

Vir said it will present additional data from its chronic hepatitis trials in November, and plans to share further data assessing a potential functional cure in the second quarter.

The San Francisco company also said it plans to release initial clinical data for VIR-5500, a treatment designed to minimize off-tumor toxicity in the first quarter.

Write to Jasmine Li at jasmine.li@wsj.com

(END) Dow Jones Newswires

November 01, 2024 15:05 ET (19:05 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2480567778"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2480567778\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2480567778?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-02 03:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2480567778","market":"us","top_or_hot":-1,"title":"Vir Shares Rally 25% on Cancer Licensing Deal With Sanofi, Trial Updates","media":"Dow Jones","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Jasmine Li \n</p>\n<p>\n  Shares of Vir Biotechnology surged after the company provided updates on its pipeline of potential treatments for hepatitis and cancer. \n</p>\n<p>\n  The stock rose 25% to $9.34 in midday trading on Friday. Shares are down 8.5% this year. \n</p>\n<p>\n  After the market closed on Thursday Vir reported lower revenue and a wider loss in the third quarter, citing higher research and development expenses from the closing its licensing deal with <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>. \n</p>\n<p>\n  The deal gives Vir the exclusive worldwide license to three T-cell engager programs with potential applications in a range of cancers, the company said. Vir also gained exclusive use of a proprietary masking platform for oncology and infectious disease. \n</p>\n<p>\n  Vir said it will present additional data from its chronic hepatitis trials in November, and plans to share further data assessing a potential functional cure in the second quarter. \n</p>\n<p>\n  The San Francisco company also said it plans to release initial clinical data for VIR-5500, a treatment designed to minimize off-tumor toxicity in the first quarter. \n</p>\n<p>\n  Write to Jasmine Li at jasmine.li@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 01, 2024 15:05 ET (19:05 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones & Company, Inc.\n</p>\n</font></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Vir Shares Rally 25% on Cancer Licensing Deal With Sanofi, Trial Updates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVir Shares Rally 25% on Cancer Licensing Deal With Sanofi, Trial Updates\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2024-11-02 03:05</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Jasmine Li \n</p>\n<p>\n  Shares of Vir Biotechnology surged after the company provided updates on its pipeline of potential treatments for hepatitis and cancer. \n</p>\n<p>\n  The stock rose 25% to $9.34 in midday trading on Friday. Shares are down 8.5% this year. \n</p>\n<p>\n  After the market closed on Thursday Vir reported lower revenue and a wider loss in the third quarter, citing higher research and development expenses from the closing its licensing deal with <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>. \n</p>\n<p>\n  The deal gives Vir the exclusive worldwide license to three T-cell engager programs with potential applications in a range of cancers, the company said. Vir also gained exclusive use of a proprietary masking platform for oncology and infectious disease. \n</p>\n<p>\n  Vir said it will present additional data from its chronic hepatitis trials in November, and plans to share further data assessing a potential functional cure in the second quarter. \n</p>\n<p>\n  The San Francisco company also said it plans to release initial clinical data for VIR-5500, a treatment designed to minimize off-tumor toxicity in the first quarter. \n</p>\n<p>\n  Write to Jasmine Li at jasmine.li@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 01, 2024 15:05 ET (19:05 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones & Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4535","symbol_name":"淡馬錫持倉","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2480567778","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2480567778","pubTimestamp":1730487900,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Vir Biotechnology surged after the company provided updates on its pipeline of potential treatments for hepatitis and cancer.The stock rose 25% to $9.34 in midday trading on Friday. Shares are down 8.5% this year.After the market closed on Thursday Vir reported lower revenue and a wider loss in the third quarter, citing higher research and development expenses from the closing its licensing deal with Sanofi.The deal gives Vir the exclusive worldwide license to three T-cell engager programs with potential applications in a range of cancers, the company said. Vir also gained exclusive use of a proprietary masking platform for oncology and infectious disease.Vir said it will present additional data from its chronic hepatitis trials in November, and plans to share further data assessing a potential functional cure in the second quarter.The San Francisco company also said it plans to release initial clinical data for VIR-5500, a treatment designed to minimize off-tumor toxicity in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4535":"淡马锡持仓","VIR":"Vir Biotechnology, Inc.","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4568":"美国抗疫概念","SNYNF":"Sanofi","BK4007":"制药"},"translate_title":"Vir股价因与赛诺菲达成癌症许可协议和试验更新而上涨25%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNYNF":1,"VIR":0.9},"content_text":"By Jasmine Li \n\n\n  Shares of Vir Biotechnology surged after the company provided updates on its pipeline of potential treatments for hepatitis and cancer. \n\n\n  The stock rose 25% to $9.34 in midday trading on Friday. Shares are down 8.5% this year. \n\n\n  After the market closed on Thursday Vir reported lower revenue and a wider loss in the third quarter, citing higher research and development expenses from the closing its licensing deal with Sanofi. \n\n\n  The deal gives Vir the exclusive worldwide license to three T-cell engager programs with potential applications in a range of cancers, the company said. Vir also gained exclusive use of a proprietary masking platform for oncology and infectious disease. \n\n\n  Vir said it will present additional data from its chronic hepatitis trials in November, and plans to share further data assessing a potential functional cure in the second quarter. \n\n\n  The San Francisco company also said it plans to release initial clinical data for VIR-5500, a treatment designed to minimize off-tumor toxicity in the first quarter. \n\n\n  Write to Jasmine Li at jasmine.li@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 01, 2024 15:05 ET (19:05 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}